Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004494 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
A Phase 1 study of Sepsis and Respiratory Distress Syndrome, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT00004494: Completed Phase 1 study of Sepsis and Respiratory Distress Syndrome, sponsored by Stony Brook University.
NCT00004494 is a Phase 1 study of Sepsis and Respiratory Distress Syndrome that has completed, run by Stony Brook University. The registered enrollment target is 18 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004494, a Phase 1 study of Sepsis and Respiratory Distress Syndrome, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
OBJECTIVES: I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome. II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.
Conditions Studied
Interventions
- DRUG vasoactive intestinal peptide
Study Locations (2)
New York
- Veterans Affairs Medical Center - Northport - Northport
- State University of New York Health Sciences Center - Stony Brook - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 1998-09 |
| Phase | Phase 1 |
What the finished NCT00004494 record still lists
NCT00004494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which vasoactive intestinal peptide is the first listed.
NCT00004494 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00004494 about?
NCT00004494 is a clinical study titled "Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis". OBJECTIVES: I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with acute respiratory distress syndrome. II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.
What is the current status of trial NCT00004494?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 1998-09.
What conditions does trial NCT00004494 study?
This clinical trial studies the following conditions: Sepsis, Respiratory Distress Syndrome, Respiratory Distress Syndrome, Adult.
What interventions are being tested in trial NCT00004494?
The interventions under investigation include: vasoactive intestinal peptide (DRUG).
Who is sponsoring clinical trial NCT00004494?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004494 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00004494's enrollment target sits among peer trials
18 83rd of 90 higher than 7 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention
RECRUITING · Phase 1
-
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
ACTIVE NOT RECRUITING · Phase 1
-
Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance
COMPLETED · Phase 1
-
Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections
COMPLETED · Phase 1
-
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
COMPLETED · Phase 1
-
The APS Phenotyping Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia